NTC signs licensing agreement with Hyundai Pharm

Published: 7-Sep-2004

Milan-based NTCPharmalicensing & Business Development has strengthened its co-operation leading Korean pharmaceutical company Hyundai Pharm Ind. Co by signing a new licensing agreement for an advanced formulation of iron protein acetyl aspartilate (IPAA) in Korea for treating iron-deficiency anaemia.


Milan-based NTCPharmalicensing & Business Development has strengthened its co-operation leading Korean pharmaceutical company Hyundai Pharm Ind. Co by signing a new licensing agreement for an advanced formulation of iron protein acetyl aspartilate (IPAA) in Korea for treating iron-deficiency anaemia.

The two companies signed their first licensing agreement in 1998.

IPAA is a new medical preparation in which iron is bound to casein by the introduction of acetylaspartic acid. The therapeutic efficacy is confirmed by the disappearance of the subjective and objective clinical symptoms typical of sideremic anaemia, such as skin or mucous pallor, tiredness, asthenia, glossitis, cheilitis, anorexia, cenesthopathy. IPAA is characterised by good local and systemic tolerability, which is correlated to its biochemical properties, and in particular to IPAA insolubility in the acid environment of the stomach.

The product is added to other drugs, marketed or under registration, that the companies have developed together for the Korean market.

'We hope to expand our market share in the field of pharmaceutical products by successfully launching this product in Korea,' commented Han-Koo Lee, ceo of Hyundai Pharm.

  

You may also like